CANbridge Life Sciences Awarded “Deal of the Year 2016 ”by China Healthcare Investment Conference for License of Cancer Candidate from AVEO


(March 31, 2017 – Beijing, China-) – CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that the China Healthcare Investment Conference awarded it “Deal of the Year 2016” for its acquisition of the worldwide rights, excluding the United States, Canada, and Mexico, to AV-203 (now CAN017), from the US company, AVEO. CAN017 is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, that CANbridge is developing for esophageal squamous cell cancer (ESCC), the most common form of the cancer in Asia. RNDer received 6,766 tickets from readers during a month voting among pharma executives, investors and experts, with the CANbridge deal garnering 4,717 votes to become the winner. James Xue, PhD, Founder and CEO of CANbridge accepted the award on March 29th at the conference in Pudong Shangri-La, Shanghai. Dr. Xue was also a panelist in the March 29th “Making Cross-Border Deals” session.

"CANbridge dedicates this award to the nearly half million newly-diagnosed Chinese esophageal cancer patients each year," said Dr. Xue, in speaking of the award. "We are investing a major effort to moving CAN017 clinical trial program forward and hope to bring this potentially life-saving therapy to esophageal cancer patients in the near future."



About Deal of the Year

Deal of the Year is a traditional annual award presented by RNDer, the leading trade media and business intelligence provider in the field of pharmaceutical and biotech. The award is to celebrate the most impressive cross-border deal in China. Seven cross-border deals in 2016 were nominated by editors at RNDer. We received 6,766 tickets from our readers during a month voting among pharma executives, investors and experts. CANbridge and AVEO’s deal of AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate got 4,717 votes and became the winner of RNDer’s Deal of the Year.

Founded by industry-recognized editors, RNDer is a leading publication providing value-added analysis for pharmaceutical and biotechnology companies doing business in China. With a mission to facilitate drug R&D and regulatory science in China, we talk to regulators and key opinion leaders from industry to piece together the China market puzzle for our readers.


About CANbridge Life Sciences

CANbridge Life Sciences, Ltd. is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan).  CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses, or obtains exclusive rights to commercialize, drug and device products that are approved in their home markets, for commercialization in China and North Asia.  

CANbridge has an agreement with EUSA Pharma, to commercialize Caphosol® in China for the prevention and treatment of oral mucositis caused by cancer treatments, and a license with Apogenix to develop, manufacture and commercialize immune-oncology therapy, APG101, for the treatment of glioblastoma multiforme in China, Macao, Hong Kong and Taiwan, where it is being developed as CAN-008. CAN-008 is currently in a Phase I/II trial in glioblastoma multiforme (GBM) in Taiwan. CANbridge also has a world-wide license (ex-North America) with AVEO Oncology to develop, manufacture and commercialize clinical-stage ErbB3 (HER3) inhibitory antibody candidate AV-203, now CAN-017. 

Led and backed by a highly-seasoned executive team, with extensive Chinese drug development experience, CANbridge has the capability to select, acquire, develop and commercialize future therapeutics and diagnostics targeting the unmet medical needs of Chinese and East Asian patients with serious or critical conditions.  

CANbridge is privately-held and headquartered in Beijing, China.  For more on CANbridge Life Sciences, please go to